Highlights
1 patent
About
Using Human Immune Cells to Deliver Therapeutic Proteins
Edity is developing an exciting new platform that harnesses the immune system to deliver therapeutic proteins direct to the cytoplasm of target cells to reprogram cells and tissue back to health.
The technology creates the opportunity to change the course of disease at the intracellular level via multiple mechanisms including protein replacement, target modulation, genetic correction and protein gain of function. Currently, the company is working across a number of indications, including oncology and genetic disease, while developing programs for regeneration and longevity.
Identity
| Name | Edity Therapeutics |
|---|---|
| Slug | edity-therapeutics |
| Type / kind | startup |
| Crunchbase ID | edity-therapeutics |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAkJTnsbQJDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ city | Rehovot |
| HQ address | Prof. Menakhem Plaut St, Rehovot, Israel |
Web & social
| Website | https://edity-tx.com |
|---|---|
| https://www.linkedin.com/company/67330457 | |
| YouTube | https://www.youtube.com/@editytherapeuticsltd.388 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsGenes
Target customers
Healthcare & Life SciencesLife SciencesBiotechnology
Business models
B2B
Tags
drug-deliveryproteinsgene-editingbiotechnologygeneticsgenomicsgenetic-disordersoncology
Funding
| Total raised | $13.6M |
|---|---|
| Current stage | Series A |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}